Online citations, reference lists, and bibliographies.
← Back to Search

Structure Of The Extracellular Region Of HER2 Alone And In Complex With The Herceptin Fab

Hyun-Soo Cho, K. Mason, K. Ramyar, A. Stanley, S. Gabelli, D. Denney, D. Leahy
Published 2003 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
HER2 (also known as Neu, ErbB2) is a member of the epidermal growth factor receptor (EGFR; also known as ErbB) family of receptor tyrosine kinases, which in humans includes HER1 (EGFR, ERBB1), HER2, HER3 (ERBB3) and HER4 (ERBB4). ErbB receptors are essential mediators of cell proliferation and differentiation in the developing embryo and in adult tissues, and their inappropriate activation is associated with the development and severity of many cancers. Overexpression of HER2 is found in 20–30% of human breast cancers, and correlates with more aggressive tumours and a poorer prognosis. Anticancer therapies targeting ErbB receptors have shown promise, and a monoclonal antibody against HER2, Herceptin (also known as trastuzumab), is currently in use as a treatment for breast cancer. Here we report crystal structures of the entire extracellular regions of rat HER2 at 2.4 Å and human HER2 complexed with the Herceptin antigen-binding fragment (Fab) at 2.5 Å. These structures reveal a fixed conformation for HER2 that resembles a ligand-activated state, and show HER2 poised to interact with other ErbB receptors in the absence of direct ligand binding. Herceptin binds to the juxtamembrane region of HER2, identifying this site as a target for anticancer therapies.
This paper references
10.1038/35052073
Untangling the ErbB signalling network
Y. Yarden (2001)
10.1073/PNAS.92.7.3046
Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein.
S. Munemitsu (1995)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
10.1016/S0092-8674(02)00963-7
Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
H. Ogiso (2002)
10.1038/sj.onc.1200873
Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation
C. L. Burke (1997)
Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation.
U. Wagner (1996)
The promise and perils of Wnt signaling through beta-catenin.
R. Moon (2002)
10.1016/b978-0-12-312411-1.x5000-8
Hormones and Signaling
B. O'Malley (1998)
10.1107/S0021889891004399
A program to produce both detailed and schematic plots of protein structures
P. Kraulis (1991)
10.1006/DBIO.2000.9816
GSK-3: new thoughts on an old enzyme.
D. M. Ferkey (2000)
e-mail: dleahy@jhmi.edu). Coordinates and structure factors are available from the Protein Data Bank under accession numbers 1N8Y (rat sHER2) and 1N8Z (human sHER2–Herceptin Fab complex)
Correspondence
Inhibition of GSK-3 β leading to the loss of phosphorylated MAP-1 B is an early event in axonal remodelling induced by WNT-7 a or lithium
F. Lucas (1998)
Molecular Biology and Cell Biology
Andrey S Krasilnikov
10.1038/374617A0
Glycogen synthase kinase-3 and dorsoventral patterning in Xenopus embryos
X. He (1995)
10.1107/S0907444998003254
Crystallography & NMR system: A new software suite for macromolecular structure determination.
A. Brünger (1998)
10.1002/(SICI)1097-0134(199710)29:2<161::AID-PROT4>3.0.CO;2-G
VL:VH domain rotations in engineered antibodies: Crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs
M. Banfield (1997)
10.1038/sj.onc.1203973
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
D. Harari (2000)
10.1126/SCIENCE.1074611
Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether
Hyun-Soo Cho (2002)
10.1107/S0108767390010224
Improved methods for building protein models in electron density maps and the location of errors in these models.
T. Jones (1991)
10.1128/MCB.19.11.7420
Cell-Extracellular Matrix Interactions Stimulate the AP-1 Transcription Factor in an Integrin-Linked Kinase- and Glycogen Synthase Kinase 3-Dependent Manner
A. Troussard (1999)
Regulation of Spemann organizer formation by the intracellular kinase Xgsk-3.
S. Pierce (1995)
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
M. Molina (2001)
10.1038/nature01148
Rho GTPases in cell biology
S. Etienne-Manneville (2002)
10.1038/236285b0
Crystal Structure
W. A. Wooster (1972)
APC binds to the novel protein EB1.
L. Su (1995)
Insulin receptor substrate2 phosphorylation is necessary for protein kinase C z activation by insulin in L 6 hIR cells
F. Oriente (2001)
10.1126/SCIENCE.2885917
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.
P. D. Di Fiore (1987)
10.1016/S0092-8674(01)00412-3
Regulation of GSK-3 A Cellular Multiprocessor
A. Harwood (2001)
10.1016/S0014-5793(99)00283-5
Binding specificities and affinities of egf domains for ErbB receptors
J. T. Jones (1999)
10.1016/S0960-9822(01)00002-1
Binding of the adenomatous polyposis coli protein to microtubules increases microtubule stability and is regulated by GSK3β phosphorylation
J. Zumbrunn (2001)
10.1073/PNAS.92.18.8498
Role of glycogen synthase kinase 3 beta as a negative regulator of dorsoventral axis formation in Xenopus embryos.
I. Dominguez (1995)
10.1016/S0960-9822(01)00142-7
CDC-42 controls early cell polarity and spindle orientation in C. elegans
M. Gotta (2001)
GSK 3 β / shaggy mediates patterning along the animal-vegetal axis of the sea urchin embryo
F. Emily-Fenouil (1998)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1146/ANNUREV.BI.56.070187.004313
Receptors for epidermal growth factor and other polypeptide mitogens.
G. Carpenter (1987)
10.1016/S0960-9822(01)00141-5
CDC-42 regulates PAR protein localization and function to control cellular and embryonic polarity in C. elegans
A. Kay (2001)
10.1107/S0021889892009944
PROCHECK: a program to check the stereochemical quality of protein structures
R. Laskowski (1993)
Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells
M A Molina (2001)
10.1101/GAD.14.15.1837
Wnt signaling and cancer.
P. Polakis (2000)
10.1093/emboj/19.13.3159
The ErbB signaling network: receptor heterodimerization in development and cancer
M. Olayioye (2000)
10.1016/S0092-8674(01)00471-8
Integrin-Mediated Activation of Cdc42 Controls Cell Polarity in Migrating Astrocytes through PKCζ
Sandrine Etienne-Manneville (2001)
Methods Enzymol
M Carson (1997)
Dissecting interactions between EB1, microtubules and APC in cortical clusters at the plasma membrane.
A. Barth (2002)
10.1107/S0907444900014736
Use of TLS parameters to model anisotropic displacements in macromolecular refinement.
M. Winn (2001)
10.1126/science.272.5264.1023
Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly
B. Rubinfeld (1996)
Jr Gene amplification methods. US patent 5
D W Denney (1998)
10.1016/S1097-2765(03)00047-9
EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.
K. Ferguson (2003)
10.1074/jbc.M202880200
Disabling Receptor Ensembles with Rationally Designed Interface Peptidomimetics*
A. Berezov (2002)
EGF activates its receptor by relieving autoinhibition of ectodomain dimerization
K. M. Ferguson
Competing interests statement The authors declare that they have no competing financial interests
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
M. Sliwkowski (1999)
10.1016/S0960-9822(01)00297-4
Critical role for the EB1 and APC interaction in the regulation of microtubule polymerization
M. Nakamura (2001)
10.1083/jcb.200203001
The adenomatous polyposis coli protein unambiguously localizes to microtubule plus ends and is involved in establishing parallel arrays of microtubule bundles in highly polarized epithelial cells
M. Mogensen (2002)
10.1038/nrm806
The subcellular destinations of apc proteins
M. Bienz (2002)
10.1016/S0955-0674(00)00264-7
Intercellular junctions and cellular polarity: the PAR-aPKC complex, a conserved core cassette playing fundamental roles in cell polarity.
S. Ohno (2001)
10.1107/S0108767393007597
AMoRe: an automated package for molecular replacement
J. Navaza (1994)
Jr Gene amplification methods
D. W. Denney (1998)
10.1016/S0092-8674(00)00114-8
Cell Signaling by Receptor Tyrosine Kinases
J. Schlessinger (2000)
10.1107/S0021889897006766
MOLREP: an Automated Program for Molecular Replacement
A. Vagin (1997)
10.1016/S0092-8674(02)00940-6
Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α
T. J. Garrett (2002)
Axin and Frat 1 interact with Dvl and GSK , bridging Dvl to GSK in the Wntmediated regulation of LEF1
L. Li (1999)
Supplementary Information accompanies the paper on Nature's website (ç http://www.nature.com/nature)
EGF activates its receptor by relieving auto-inhibition of ectodomain dimerization
K M Ferguson
10.1016/B978-012312411-1/50006-8
EGF Family Receptors and Their Ligands in Human Cancer
C. Tang (1998)
10.1006/PREP.2000.1331
A mammalian expression vector for expression and purification of secreted proteins for structural studies.
D. Leahy (2000)
10.1002/BIP.360340711
Shape complementarity at protein–protein interfaces
R. Norel (1994)



This paper is referenced by
Immunohistochemical Study of HER 2 / neu Overexpression in Adenoid Cystic Carcinoma of Salivary Glands
J. Salehinejad (2014)
10.1039/b927393j
The functional capacity of the natural amino acids for molecular recognition.
S. Birtalan (2010)
10.1016/J.GENE.2005.10.018
Epidermal growth factor receptor (EGFR) signaling in cancer.
N. Normanno (2006)
10.1038/oncsis.2016.25
A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
Y. Meng (2016)
10.1038/s41423-020-00555-x
Clinical development of CAR T cell therapy in China: 2020 update.
Jianshu Wei (2020)
10.1200/JCO.2008.17.3989
Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients.
A. Leary (2009)
10.1016/j.jmb.2011.01.011
Site-specific coupling and sterically controlled formation of multimeric antibody fab fragments with unnatural amino acids.
B. M. Hutchins (2011)
10.1021/mp500759p
Conformational and Colloidal Stabilities of Isolated Constant Domains of Human Immunoglobulin G and Their Impact on Antibody Aggregation under Acidic Conditions.
Seiki Yageta (2015)
10.1201/B17634-5
Functional Role of Membrane Lipids in EGF Receptor Dynamics and Regulation
M. Grzybek (2014)
10.1074/JBC.M411020200
Conformational HER-2/neu B-cell Epitope Peptide Vaccine Designed to Incorporate Two Native Disulfide Bonds Enhances Tumor Cell Binding and Antitumor Activities*
N. Dakappagari (2005)
10.1042/BST0320742
Active and inactive conformations of the epidermal growth factor receptor.
K. Ferguson (2004)
Anti-HER 2 vaccines : new prospects for breast cancer therapy
M. Z. Ladjemi (2017)
10.1021/acschembio.9b00016
High-Throughput Quantification of Surface Protein Internalization and Degradation.
Jakob C Stüber (2019)
10.4161/mabs.4.2.19202
Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system
G. Yin (2012)
Elucidating Molecular Mechanisms of ERBB2/Neu-Induced Mammary Tumorigenesis
M. Landis (2006)
10.1021/BC050348P
HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb.
R. Shukla (2006)
10.1309/99AE032R9FM8WND1
HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.
D. Hicks (2008)
10.1016/j.ccr.2008.03.010
A molecular view of anti-ErbB monoclonal antibody therapy.
D. Leahy (2008)
10.1038/nrc2656
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
J. Baselga (2009)
10.1002/9780470485408.CH31
Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates
Ningyan Zhang (2009)
10.7170/JSIS.V1I2.11
Amplification of the Oncogene HER2 in Breast Cancer: Molecular Basis and Therapeutic Significance
Francini Matos Lima Lin (2012)
10.1038/nbt.2354
Direct identification of ligand-receptor interactions on living cells and tissues
Andreas P. Frei (2012)
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbBLigands and Remain Dependent on the ErbBReceptor Network
C. Ritter (2007)
Will Single-Time Tumor Profiling and a ‘ ‘ Guilt by Association ’ ’ ApproachAllowUs toOutsmartHER 2-PositiveBreastCancer ? 55
C. Arteaga (2007)
10.4161/mabs.3.5.17228
The improvement of an anti-CD22 immunotoxin
Seiji Kawa (2011)
10.1016/J.CANLET.2004.11.015
Antitumor activity of HER-2 inhibitors.
S. Rabindran (2005)
10.18632/oncotarget.19821
Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children
M. Merker (2017)
10.1002/anie.201410049
Rational design of a humanized glucagon-like peptide-1 receptor agonist antibody.
Y. Zhang (2015)
Impact of target antigen properties on antibody effector mechanisms
K. Cleary (2015)
10.4161/cbt.8.24.10131
Targeting HER2 signaling pathway for radiosensitization: Alternative strategy for therapeutic resistance
Mina No (2009)
10.36069/jols/20191204
Regulation and New Treatment Strategies in Breast Cancer.
Rosa-Maria Ferraiuolo (2019)
10.1016/B978-0-12-374145-5.00005-X
Antibody–Antigen Recognition and Conformational Changes
R. Stanfield (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar